<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056290</url>
  </required_header>
  <id_info>
    <org_study_id>BB-IND 11572</org_study_id>
    <secondary_id>NIH #0104-467</secondary_id>
    <nct_id>NCT00056290</nct_id>
  </id_info>
  <brief_title>VEGF Gene Transfer for Diabetic Neuropathy</brief_title>
  <official_title>p.VGI.1 (VEGF2) Gene Transfer for Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Losordo, Douglas, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Losordo, Douglas, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This gene therapy study is being conducted to evaluate intramuscular gene transfer using VEGF
      (Vascular Endothelial Growth Factor) in patients with diabetic neuropathy in the legs. This
      condition causes a decrease in feeling and sensation due to diabetes. VEGF is DNA, or genetic
      material that is injected into the muscles of the leg. Once in the leg, it has been shown to
      cause new blood vessels to grow under a variety of conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VEGF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VEGF</intervention_name>
    <description>3 sets of injections, at 2 week intervals</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VEGF</intervention_name>
    <description>3 sets of injections, at 2 week intervals</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        To be eligible to enroll and remain in the study, patients must meet the following
        criteria:

          -  Be at least 21 years old.

          -  Have type I or type II diabetes mellitus and require oral anti-hyperglycemic agents or
             insulin.

          -  Have peripheral neuropathy related to diabetes.

        Exclusion criteria

        Patients are to be excluded from the trial if any of the following conditions are met:

          -  Have a history of cancer (other than non-melanoma skin cancer or in-situ cervical
             cancer) in the last five years.

          -  Be unable to meet study requirements, including approximately 7-9 out-patient visits
             over a 12 month period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan H Ropper, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steward St. Elizabeth's Medical Center of Boston, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Caritas St. Elizabeth's Medical Center Cardiovascular Research/DVM-4-SMC</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Neuropathy Research Center, Neurological Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.semc.org</url>
    <description>Caritas St. Elizabeth's Medical Center of Boston</description>
  </link>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2003</study_first_submitted>
  <study_first_submitted_qc>March 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2003</study_first_posted>
  <last_update_submitted>November 10, 2010</last_update_submitted>
  <last_update_submitted_qc>November 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Feinberg Cardiovascular Research Institute, Program in Cardiovascular Regenerative Medicine</name_title>
    <organization>Northwestern University, Northwestern Memorial Hospital</organization>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Neuropathy</keyword>
  <keyword>Peripheral Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

